Publications by authors named "P Bossuyt"

Claim this Profile
V
Vedolizumab in early and late Crohn's disease (LOVE-CD): a phase 4 open-label cohort study.
Geert R D'Haens, Mark Löwenberg, Filip Baert, Peter Bossuyt, Tamás Molnár

Lancet Gastroenterol Hepatol· January 2026

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The win ratio for evaluating edoxaban versus dalteparin for cancer-associated venous thromboembolism: an analysis of the randomized Hokusai VTE cancer trial.
Nick van Es, Luuk J J Scheres, Kristen M Sanfilippo, Harry Büller, Marc Carrier, Patrick M Bossuyt

J Thromb Haemost· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Multi-stakeholder validation of an evidence-based core set of quality indicators for IBD in Belgium.
Liselotte Fierens, Frank E Rademakers, Peter Bossuyt, Filip Baert, Didier Baert

BMC Health Serv Res· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Higher Vedolizumab Clearance Associates with Poor Therapeutic Outcomes during Intravenous Vedolizumab Maintenance Therapy in Crohn's Disease.
Suzanne I Anjie, Geert R D'Haens, Filip Baert, Peter Bossuyt, Frank Hoentjen

Inflamm Bowel Dis· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Risk factors for dysplastic lesions in the proximal stomach in patients with familial adenomatous polyposis.
Hicham Bouchiba, Arthur S Aelvoet, Barbara A J Bastiaansen, Patrick M M Bossuyt, Evelien Dekker

Endosc Int Open· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis